FindTrial
Sign In

Vilanterol

DRUG10 trials

Sponsors

GlaxoSmithKline

Conditions

AsthmaPulmonary Disease, Chronic Obstructivechronic obstructive airways disease (COPD)

Phase 1

Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects
CompletedNCT00625196
GlaxoSmithKlineAsthma
Start: 2008-02-27End: 2008-05-06Updated: 2017-08-21

Phase 2

Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children
CompletedNCT01573767
GlaxoSmithKlineAsthma
Start: 2012-04-30End: 2014-04-30Updated: 2017-01-09

Phase 3

Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma
CompletedNCT01181895
GlaxoSmithKlineAsthma
Start: 2010-09-01End: 2011-08-26Updated: 2017-11-08
Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease
CompletedNCT01313676
GlaxoSmithKlinePulmonary Disease, Chronic Obstructive
Start: 2011-01-25End: 2015-07-15Updated: 2018-08-06
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
CompletedNCT01336608
GlaxoSmithKlinePulmonary Disease, Chronic Obstructive
Start: 2011-03-04End: 2014-11-04Updated: 2017-11-08
RELOVAIR® Lung Deflation Study
CompletedNCT01691885
GlaxoSmithKlinePulmonary Disease, Chronic Obstructive
Start: 2012-11-30End: 2014-08-31Updated: 2016-10-27
Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT02105974
GlaxoSmithKlinePulmonary Disease, Chronic Obstructive
Start: 2014-04-07End: 2015-07-08Updated: 2018-01-24
A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma
CompletedNCT02446418
GlaxoSmithKlineAsthma
Start: 2015-07-09End: 2017-07-20Updated: 2019-01-14

Phase 4

Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
CompletedNCT01957150
GlaxoSmithKlinePulmonary Disease, Chronic Obstructive
Start: 2014-01-28End: 2018-03-26Updated: 2019-04-10
A 24-week treatment, multi-center, randomized, double-blind, double-dummy, parallel group study to compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in subjects with chronic obstructive pulmonary disease (COPD)
Active, not recruitingNL-OMON45687
GlaxoSmithKlinechronic obstructive airways disease (COPD)
Start: 2017-06-16Target: 80Updated: 2024-02-28

Related Papers

Estimating individual treatment effects on COPD exacerbations by causal machine learning on randomised controlled trials
Thorax2023-04-0317 citations
Pragmatic randomised controlled trials in COPD and asthma: how to guide clinical practice
BMJ Open Respiratory Research2022-09-013 citations
Scores of Health-Related Quality of Life Questionnaire Worsen Consistently in Patients of COPD: Estimating Disease Progression over 30 Years by SReFT with Individual Data Collected in SUMMIT Trial
Journal of Clinical Medicine2020-08-185 citations
<p>The Summit Score Stratifies Mortality and Morbidity in Chronic Obstructive Pulmonary Disease</p>
International Journal of COPD2020-07-013 citations
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
2020-06-0510 citations
Chronic Obstructive Pulmonary Disease as a Predictor of Cardiovascular Risk: A Case-Control Study
COPD Journal of Chronic Obstructive Pulmonary Disease2019-12-137 citations
Association of platelet count with all-cause mortality and risk of cardiovascular and respiratory morbidity in stable COPD
Respiratory Research2019-05-0835 citations
Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial
BMJ Open Respiratory Research2019-05-0153 citations
Impact of pre-enrolment medication use on clinical outcomes in SUMMIT
ERJ Open Research2019-02-015 citations
Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease.
2018-09-0140 citations
β-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT
Annals of the American Thoracic Society2018-02-0626 citations
Serum Levels of Club-Cell Protein 16 (CC-16), Surfactant Protein D (SPD), soluble Receptor of Glycation End-products (sRAGE), Fibrinogen and C-Reactive Protein (CRP) and FEV1 Decline, Exacerbations and Mortality in SUMMIT
2017-09-01
Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk
American Journal of Respiratory and Critical Care Medicine2017-07-2461 citations
Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk
Heart2017-04-1748 citations
A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
2016-12-0217 citations
Pulse wave velocity (PWV) in patients (pts) with moderate COPD and cardiovascular risk: The effect of an inhaled long-acting β<sub>2</sub>-agonist/corticosteroid (SUMMIT)
2016-09-012 citations
Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
2016-04-28323 citations
Randomised trial of once-daily vilanterol in children with asthma on inhaled corticosteroid therapy.
2016-04-0512 citations
Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids.
2014-06-1315 citations